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Abstract
Despite implications for carcinogenesis and other chronic diseases, basic mechanisms of p53 and 
its variants in suppressing Bcl-2 levels, are poorly understood. Bcl-2 sustains mucous cell 
metaplasia, whereas p53−/− mice display chronically increased mucous cells. Here we show that 
p53 decreases bcl-2 mRNA half-life by interacting with the 5’ untranslated region (UTR). The 
p53-bcl-2 mRNA interaction is modified by the substitution of proline by arginine within the p53 
proline-rich domain (PRD). Accordingly, more mucous cells are present in primary human airway 
cultures with p53Arg compared with p53Pro. Also, the p53Arg compared with p53Pro displays 
higher affinity to and activates the promoter region of SAM-pointed domain-containing Ets-like 
factor (SPDEF), a driver of mucous differentiation. On two genetic backgrounds, mice with 
targeted replacement of prolines in p53 PRD show enhanced expression of SPDEF and Bcl-2 and 
mucous cell metaplasia. Together, these studies define the PRD of p53 as a determinant for 
chronic mucus hypersecretion.
Introduction
The importance of Bcl-2 and its family members in cell survival, differentiation, and 
oncogenesis has been demonstrated extensively. Bcl-2 overexpression inhibits cell death and 
can promote cell transformation when present together with mutations of certain 
oncogenes1,2. For example, combined expression of Bcl-2 and c-Myc leads to the rapid 
transformation of lymphocytes and other cell types3,4. Consistent with its oncogenic 
function, Bcl-2 is aberrantly overexpressed in a wide range of human tumors, including B-
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cell and T-cell lymphomas5 and non small cell lung carcinomas6. This central gate-keeping 
role of Bcl-2 necessitates a highly controlled regulation of its expression. Despite its 
functional importance, the molecular mechanisms regulating Bcl-2 expression are largely 
unknown.
We and others have reported on evidence that p53 affects transcriptional activity of a partial 
Bcl-2 promoter in pulmonary epithelial cells7–9, which was consistent with numerous 
studies reporting that p53 acts as a transcription factor10. The bcl-2 gene is composed of 3 
exons whereby exons 1 and 2 are separated by a long intron of 150kb11. Exon 1 contains the 
5’ up-stream region with promoters P1 and P2 and part of the protein coding open reading 
frame (ORF)12. Exon-2 encodes for parts of the ORF and the 3’UTR and the remainder of 
which is encoded by exon 3. The P2 promoter region contains a CCAAT box and a TATA 
element and is the primary suppressor of the P1 promoter. This negative regulatory region is 
highly conserved across species and may be modulated by the M region of the bcl-2 
promoter13.
Our previous studies show that pulmonary inflammation initiates airway epithelial cell 
proliferation and Bcl-2 expression in proliferating epithelial cells14,15. Gain- and loss-of-
function studies showed that Bcl-2 expression sustains hyperplastic epithelial cells, and 
Bcl-2 expression is elevated in airway mucous cells of subjects with cystic fibrosis16, in 
patients with chronic mucous hypersecretion (CMH)17, and in airway epithelium of 
asthmatics18.
Chronic obstructive pulmonary disease (COPD) encompasses a spectrum of diseases, with 
chronic bronchitis (CB) at one end and emphysema at the other. The classic definition for 
CB is chronic cough and sputum production for at least 3 months per year for two 
consecutive years19; although it is not clear whether CB is a disease of large airways only or 
whether inflammation in small airways causes mucous cell metaplasia that plays a distinct 
role in the development of CB. While all smokers develop an inflammatory response, CB is 
only observed in a subset of heavy smokers20, and in approximately half of these individuals 
CB persists even after quitting smoking21. Smokers with CB are at higher risk of increased 
exacerbation rate22, longer recovery period following acute COPD exacerbations23, worse 
health-related quality of life including general health status, severe respiratory symptoms, 
increased physical activity limitation24, and have worse lung function25. In addition, among 
subjects with COPD, those with CB are at higher risk for accelerated decline in lung 
function34, and lung cancer26,27, and are prone to increased mortality23, especially after lung 
volume reduction surgery28. Persistent CB in former smokers may be due to some intrinsic 
factors such as susceptibility genes that predispose them to this condition. Therefore, 
intervention strategies for reducing CB requires identification of endogenous factors 
including genetic polymorphisms that make smokers susceptible to sustained chronic 
mucous hypersecretion.
In the present study, we show that when Bcl-2 regulation is analyzed in the context of the 
entire promoter construct, p53 primarily regulates Bcl-2 levels by reducing the mRNA half-
life rather than affecting promoter activity. When studying the detailed mechanisms of p53-
induced suppression of Bcl-2 regulation and how that may affect the role of sustaining 
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metaplastic mucous cells, we determined that two p53 variants, due to a polymorphism at 
codon 72, differentially affect bcl-2 mRNA half-life and are associated with increased CB in 
smokers. In addition, microarray expression analysis of primary human airway epithelial 
cells (HAECs) homozygote for the two genotypes pointed to the differential regulation of 
SPDEF, a protein that is sufficient and necessary to drive the mucous regulatory phenotype 
in airway cells. Both the high mucous secretory phenotype and increased Bcl-2 and SPDEF 
levels were also observed in mice when the highly conserved proline-rich domain of p53, 
where the corresponding human variant resides, was modified. Together, these studies 
provide the fundamental understanding of chronic mucous hypersecretion and may help not 
only the detection and early management of this debilitating disease but also the 
development of effective therapies.
Results
Absence of p53 prolongs mucous cell metaplasia
Our previous studies have shown that Bcl-2 is expressed in metaplastic mucous cells in 
various animal models of chronic bronchitis and asthma14,15,29. Furthermore, we have 
shown that Bcl-2 sustains metaplastic mucous cells16 and that p53 is involved in regulating 
Bcl-2 expression13. To investigate whether the regulation of Bcl-2 by p53 translates into 
modification of mucous cell metaplasia, the extent of MCM in airway epithelia at airway 
generations 3, 4, and 5 was quantified in p53+/+ and p53−/− mice at 5, 8, and 12 d after 
intranasal instillations of LPS. In p53+/+ mice the numbers of mucous cells/mm basal 
lamina were increased at 5 and 8 d post instillation and returned to baseline at 12 d (Fig. 
1A). However, in p53−/− mice MCM remained elevated at 12 d and was higher than that 
observed in p53+/+ at the same time point (Fig. 1A). Immunostaining of lung tissue sections 
from p53+/+ and p53−/− mice at 12 d post LPS instillation showed that Bcl-2 and Muc5ac 
positivity was significantly higher in p53−/− mice (Fig. 1B) both when quantified as 
percentage of total epithelial cells or as numbers/mm basal lamina (Fig. 1C, D). These 
results suggest that Bcl-2 expression was sustained in p53−/− mice causing persistent MCM, 
while Bcl-2 was downregulated in p53+/+ mice allowing the resolution of MCM at 12 d.
p53 affects bcl-2 mRNA levels and stability
Several studies have documented a suppressive effect of p53 on Bcl-28,9 and an inverse 
correlation of p53 and Bcl-2 levels for squamous lung cancers30. Consistent with these 
reports, the p53-sufficient H23 and AALEB cells showed reduced bcl-2 mRNA and protein 
levels compared to p53-deficient SAOS-2 cells (Supplementary Fig. 1A, B). These results 
were further confirmed in p53-deficient SAOS-2 cells stably expressing p53 or the 
respective controls (Supplementary Fig. 1C) and in H1299 cells that were stably transfected 
with a temperature-sensitive form of p53 (H1299p53ts) (Supplementary Fig. 1D). Similarly, 
HCT116 cells deficient in p53 (Fig. 2A) and primary murine airway epithelial cells 
(MAECs) from p53−/− mice (Fig. 2D) expressed increased bcl-2 mRNA levels compared to 
the respective wild-type controls.
We previously observed that the P2 promoter region of the bcl-2 gene, when analyzed alone 
or in the absence of P1 or M regions, interacts with and was suppressed by p5313. To further 
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evaluate the effect of p53 on P2 promoter activity in the context of the full-length promoter 
that contains the P1, M, and P2 regions, we compared the promoter activities of constructs 
containing the progressively deleted P2 region in p53-sufficient A549 and p53-deficient 
H1299 cells (Supplementary Table 1). The activities of the P1-M-P2 promoter were lower in 
both cells lines when > 140 bp of the P2 region was present (Supplementary Fig. 2A). 
Similarly, when the same constructs were tested in H1299 cells stably transfected with the 
temperature-sensitive p53 (p53ts), the P2 region effectively reduced promoter activity 
regardless of the p53 activation status (Supplementary Fig. 2B). The promoter activity 
assays repeatedly showed that p53 minimally suppressed bcl-2 promoter activity, and 
removal of the entire P2 region affected promoter activity only by a factor of 2–3. In fact, 
promoter activity appeared to be increased when p53 was activated at 32°C (Supplementary 
Fig. 2B). These findings did not adequately explain the >10-fold suppression of Bcl-2 
expression by p53.
To further evaluate the reason for reduced Bcl-2 levels in p53-sufficient cells, we 
investigated whether p53 may affect bcl-2 mRNA stability. Bcl-2 mRNA half-life was 
significantly longer in the p53-deficient H1299 and SAOS-2 cells compared to the p53-
sufficent A549 and AALEB cells (Supplementary Fig 2C). The effect of p53 was further 
confirmed by the observation that bcl-2 mRNA half-life was longer in p53−/− HCT116 cells 
and in primary MAECs from p53−/− mice compared to the p53+/+ counterparts (Fig. 2B, E 
and Supplementary Fig. 2D, E). This shorter half-life in bcl-2 mRNA translated into lower 
Bcl-2 protein levels in p53 sufficient HCT116 p53-deficient cells (Fig. 2C). Together, these 
results showed that p53 enhances the degradation of bcl-2 mRNA.
p53 interacts with the P2 region within the 5'UTR of bcl-2 mRNA
While the role of p53 as a transcriptional regulator is extensively studied, the role of p53 in 
regulating mRNA stability is unknown. Because p53 affected bcl-2 mRNA stability and p53 
interacted with the P2 region, we investigated whether this region is part of the 5'UTR of 
bcl-2 mRNA. Because mechanisms involving immortalization can introduce possible 
artifacts in cell lines, we investigated whether the 5'UTR also extends to the P1 region by 
preparing bcl-2 RNA from primary HAECs and mapping the transcriptional start sites using 
5'RACE. Primers designed to amplify various regions within the 5'UTR identified four 
different transcriptional start sites: T1, T2, T3, and T4. Sequence analysis revealed that T1 
and T2 originate within the P1 region at −1778 and −1313, respectively (Supplementary Fig. 
3A). T3 and T4 were localized within the P2 region of bcl-2 gene, and transcriptional start 
sites were mapped to nucleotides −465 and −176 upstream of the open reading frame, 
respectively (Supplementary Fig. 3A). To further validate the findings from the 5'RACE, we 
used primers specific to either P2 or M regions for RT-PCR using DNase-treated RNA that 
was isolated from various epithelial cell lines. Both sets of primers successfully amplified 
products specific to the P2 (Supplementary Fig. 3B) and M (Supplementary Fig. 3C) regions 
in RNA isolated from AALEB and SAOS-2 cell lines. These findings further confirmed that 
P2 sequences are part of the Bcl-2 transcript not only in primary cells, but also in other cell 
types assayed, including cancer cells.
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We also investigated whether P2 sequences are transcribed when they are present as 
promoter-luciferase constructs in which sequences representing the 3’UTR are excluded. 
The P2 and M regions were detected by RT-PCR in A549 and H1299 cells that were 
transfected with luciferase constructs containing P1-M-P2 or P2 promoter regions using 
forward primers specific for P2 or M and luciferase cDNA-specific reverse primers 
(Supplementary Fig. 3D, E, F). Collectively, our findings confirmed that sequences of P2 
region are represented within the 5'UTR of Bcl-2 transcripts in several cell lines and that the 
absence of 3'UTR sequences of bcl-2 mRNA did not affect the transcriptional start site of 
bcl-2 gene.
In addition, the bcl-2 transcripts for T1, T2, T3, and T4 were successfully amplified by RT-
PCR using specific primers designed within the 5'UTR (Fig. 2F). These results demonstrate 
that p53 interacts with the bcl-2 transcripts and suggest that P2 sequences on bcl-2 mRNA 
could represent sites of interaction with p53. Because our results demonstrated that P2 
sequences are part of bcl-2 mRNA 5'UTR, we next investigated whether p53 interacts with 
bcl-2 mRNA.
A P2 region mediates p53-dependent destabilization of bcl-2 mRNA
The interaction of p53 with the 5'UTR suggested that the P2 region is responsible for the 
p53-dependent degradation of bcl-2 mRNA. Previous findings have reported that the critical 
region for p53 interaction with the Bcl-2 promoter lies within P2 region8,13,31. To identify 
5'UTR sequences within bcl-2 mRNA that are responsible for p53-dependent bcl-2 mRNA 
decay, HCT116p53+/+ cells were transfected with P1-M-P2 luciferase constructs that 
contain progressive deletions within P2 (Supplemental Information, Table 1). Luciferase 
mRNA half-life (Fig. 2G and Supplementary 2F) and luciferase activity (Fig. 2H) were 
reduced drastically from ~4.5 h in P1-M-P2Δ4 to ~1–2 h in P1-M-P2Δ5 construct, 
suggesting that the deleted 66 nucleotides (regions –423 to –489) in P1-M-P2Δ5 were 
important for p53-dependant RNA degradation.
To confirm that the 66-nucleotide region interacts with p53, we first conducted RNA pull 
down assays using in vitro transcribed bcl-2 mRNA. For this purpose, we subcloned the P2 
fragment into the PCR2.1 dual promoter vector to generate sense and anti-sense biotinylated 
mRNAs and found that p53 was only detected in pull-down products using sense mRNA 
(Supplementary Fig. 3G). Hence, interaction of p53 with bcl-2 mRNA was confirmed by 
both p53 antibody and bcl-2 mRNA pull-downs.
These results were confirmed by in vitro RNA pull-down assays using a short synthetic 50 
nucleotide construct that comprises nucleotides −443/−429. To further delimit the site of 
interaction, mutations were introduced by changing the first or second 8 nucleotides or by 
modifying the 16 nucleotides in sets of 4 nucleotides (representing the 16 nucleotides in P2–
443/−429) to random sequences as shown in Supplementary Table 2. All of the mutations 
disrupted p53 interaction with this region because in vitro RNA prepared from a control 
nucleotide sequence within the P2 region (−608/−582) did not show p53 binding suggesting 
that the interaction is specific to these 16 nucleotide sequence (Supplementary Fig. 3H). To 
further characterize the sequences within the 66 nucleotide region that interact with p53, two 
deletion mutants, P2Δ−482/−468 and P2Δ−443/−429 were generated using site-directed 
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mutagenesis. RNA pull-down assays using these deletion mutants revealed that the 16 
nucleotides (−443/−429) were important for the interaction with p53 (Fig. 2I).
To determine the influence of these nucleotides on mRNA half-life in vivo, we deleted the 
corresponding sequence in P1-M-P2 to generate P1-M-P2Δ(−443/−429)-luciferase construct 
and compared the luciferase mRNA half-life following transfection of HCT116p53+/+ cells. 
The luciferase mRNA half-life (Fig. 2J and Supplementary Fig. 2G) and luciferase activity 
were increased by approximately 2-fold (Fig. 2L) for the P1-M-P2 compared to the P1-M-
P2Δ(−443/−429) luciferase constructs, respectively, suggesting that p53 must interact with 
these sequences to destabilize the mRNA. Furthermore, introducing 4 nucleotide mutations 
at loci −443/−439 and −433/−429 within the P1-M-P2-luciferase construct did not affect 
luciferase mRNA half-life (Fig. 2J and Supplementary Fig. 2G), suggesting that merely 
mutating 4 nucleotides is not sufficient to completely abrogate the interaction of p53 in cells. 
Overall, these results show that the 16 nucleotide region within P2 is crucial for the 
interaction of p53 with the bcl-2 mRNA. This reduction in bcl-2 mRNA half-life by p53Pro 
suggests that the PRD of p53 plays an important role in this decay process. To further study 
the possible differences in the interaction of p53Arg and p53Pro with bcl-2 mRNA, we 
performed a pull-down assay using p53 antibody or IgG1 as control from H1299 parent 
cells, H1299p53tsArg, and H1299p53tsPro cells. p53 was absent in the parent H1299 cells 
and bcl-2 mRNA was greater in pull-down products from H1299p53tsArg compared to 
H1299p53tsPro cells even when normalizing for the reduced p53Pro levels detected in the 
pull-down products (Fig. 2L), supporting the idea that p53Arg has a higher affinity to the 
bcl-2 mRNA than p53Pro.
Genetic variation in p53 is associated with mucous hypersecretion
Because Bcl-2 sustains mucous cells that may be responsible for increased mucous 
hypersecretion in chronic diseases, such as cystic fibrosis16 and chronic bronchitis29, we 
wanted to investigate whether the differential regulation of Bcl-2 by p53 could be associated 
with increased chronic mucous hypersecretion in humans. First, we tested whether we can 
identify single nucleotide polymorphisms (SNPs) within the 5'UTR of Bcl-2 mRNA that 
affects p53-dependant RNA degradation and Bcl-2 expression. We sequenced the highly 
conserved P2 region in 200 individuals from the Lovelace Smokers Cohort (LSC) and were 
unable to identify single nucleotide polymorphisms within this highly conserved region. 
Because p53 has a single nucleotide polymorphism (SNP) at codon 72 (rs1042522) that 
modifies the common amino acid, arginine encoded by CGC, to a proline encoded by CCC, 
we next tested the idea whether the two p53 variants affect the interaction with 5'UTR 
sequences within bcl-2 mRNA. The Pro at codon 72 constitutes the second of the five PXXP 
(where P indicates proline and X indicates any amino acid) within the proline-rich domain 
(aa 61–94)32,33 and two independent cohort studies had found that the p53Pro variant is 
associated with attenuated decline in lung function in humans34,35. Because of the finding 
that p53 is a critical regulator of bcl-2 mRNA and the resolution of MCM we tested whether 
polymorphisms within p53 may be associated with CMH in the LSC.
Initially, we genotyped participants of the LSC when only 1102 women were enrolled of 
whom 370 participants had CMH as defined by having self-reported cough and productive 
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phlegm for 3 months a year for at least 2 consecutive years36 and 732 did not. Of the 1102 
women, 77 (7%) were homozygous p53Pro, 606 (55%) homozygous p53Arg, and 419 (38%) 
heterozygous p53Arg/Pro. We found that after adjusting for age and smoking duration, 
subjects who are homozygous for the rare p53Pro allele had a significantly reduced odds for 
chronic bronchitis compared to those with the p53Arg genotype (OR=0.48, p=0.03).
The p53 PRD is important for interaction with bcl-2 mRNA
To investigate whether the p53 SNP affects bcl-2 mRNA half-life and to possibly identify 
the domain in p53 that interacts and destabilizes bcl-2 mRNA, we compared bcl-2 mRNA 
levels and half-lives in three HAECs individually each homozygous for the p53Arg and 
p53Pro variants. We found that after averaging the bcl-2 mRNA levels in HAECs with the 
p53Arg variant (HAECArg) were approximately 2-fold greater than in p53Pro HAECs (Fig. 
3A). Bcl-2 mRNA half-life was >10 h in primary HAECs, irrespective of genotype, when 
p53 was not activated but following activation of p53 by irradiating these cells to 10 mJ UV 
light, bcl-2 mRNA half-life was reduced to 1.2 h in HAECPro and to 7 h in HAECArg cells 
(Fig. 3B). This reduction in bcl-2 mRNA half-life by p53Pro suggests that the PRD of p53 
plays an important role in this decay process. Bcl-2 protein levels were also reduced in 
HAECPro compared to HAECArg cells (Fig. 3C).
To test whether the HAECPro would also express less mucus compared to HAECArg cells, 
we identified 10 HAEC each from individuals homozygous for p53Pro and p53Arg and 
differentiated them individually in culture over 21 d at air-liquid-interface (ALI) on 
Transwell membranes. When averaged, MUC5AC mRNA levels in these cultures were 
significantly lower in HAECPro compared to HAECArg (Fig. 3D). In addition, HAECPro 
cultures exhibited less secreted mucus (Fig. 3E) and mucous cells per mm basal lamina 
compared to HAECArg cultures (Fig. 3F). These results showed that the p53Pro and p53Arg 
genotypes affected the mucous phenotype.
The polymorphism at codon 72 affects the mucous regulatory network
In airway epithelial cells, increased survival per se is not sufficient to provide the mucous 
differentiation phenotype, suggesting that p53Arg may be controlling genes that affect the 
mucous differentiation pathway. Therefore, we isolated RNA from 10 each differentiated 
HAECPro and HAECArg cultures and interrogated all expressed genes by microarray 
analysis. One of the genes found to be expressed at significantly lower levels in HAECPro 
compared to HAECArg cultures was SPDEF. From the list of genes identified to be 
differentially expressed, we focused on SPDEF, because it has recently been described as 
being a transcription factor sufficient to cause goblet cell differentiation of Clara cells37 and 
as a regulator of the transcriptional network mediating the goblet cell differentiation and 
mucus hyperproduction associated with chronic pulmonary disorders38. Differences in 
expressed genes were validated using qRT-PCR and showed that expression of MUC5AC, 
MUC5B, and SPDEF were reduced in HAECPro compared to HAECArg cultures (Fig. 3G). 
In addition, using adenoviral expression vectors forced expression of p53Pro in HAECArg 
cultures from 3 individuals significantly reduced expression of MUC5AC, MUC5B, and 
SPDEF mRNAs (Fig. 3H) while expression of p53Arg in HAECPro cultures from 3 
individuals increased expression of these genes reversing the endogenous levels of these 
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mRNAs (Fig. 3I). In addition, suppression of Bcl-2 or SPDEF using retroviral shRNA 
vectors reduced MUC5AC mRNA levels in HAECArg cultures (Supplementary Fig. 4A, B, 
C, D). These findings further demonstrated that it is the genotype of p53 that determined 
expression of genes driving the mucous regulatory phenotype.
While Bcl-2 may sustain hyperplastic mucous cells, we assumed that SPDEF may be 
responsible for the differentiation of the HAECArg cultures to express the mucous 
phenotype. Therefore, we investigated whether the promoter region of SPDEF may be 
driven differently by two p53 variants to cause the observed differences in mucous 
differentiation of HAECs. We identified two putative p53 response elements within 1 kb 
upstream of the SPDEF transcriptional start site and cloned this region into pGL3 Basic 
containing a luciferase reporter and tested activation in H1299tsArg and H1299tsPro cells. 
Following transfection with the luciferase construct and activation of the temperature-
sensitive p53 by shifting cells from 37° to 32°C for 18 h, the SPDEF promoter activity was 
consistently 2-fold lower in p53Pro versus p53Arg cells (Fig. 3J). These findings suggested 
that p53Arg has a higher affinity to the SPDEF promoter. Therefore, we performed 
chromatin immunoprecipitation (ChIP) assays using p53 antibodies and found that the 0.3 
kB region of the SPDEF promoter was recovered at significantly higher levels from 
H1299tsArg compared to H1299tsPro cells (Fig. 3K). The 4 kB upstream region was used as 
a negative control and showed little interaction in both cell lines (Fig. 3L). These findings 
confirmed that p53-SPDEF promoter binding exhibited a significantly higher affinity in 
H1299tsArg versus H1299tsPro cells.
The p53 response element is defined by two canonical decamers separated by a spacer of 0–
13 nucleotides39. The SPDEF promoter region contained two (RRRCWWGYYY) motifs 
with a four nucleotide spacer. Because the core region (CWWG) is critically important for 
p53 binding39, deletion mutations were generated by removing six nucleotides for each of 
the two motifs in the core region to form two different 6 NT deletions termed Mut11 and 
Mut21. The empty plasmid, Mut11, and Mut21 constructs when tested in the parental 
H1299, H1299tsArg, and H1299tsPro cell lines showed that while p53Arg is better than 
p53Pro in activating the wild-type promoter, SPDEF promoter activity was significantly 
reduced in both Arg and Pro cell lines when the core regions of the p53 response elements 
were absent (Fig. 3K). These findings confirmed that p53 activated SPDEF promoter by 
interacting with these conserved response elements.
Susceptibility to death in cells harboring p53Arg or p53Pro
Bcl-2 suppresses DNA damage-induced cell death40. Because p53Pro drastically reduced 
bcl-2 mRNA stability, we investigated whether cell death is enhanced in p53Pro-expressing 
cells that are grown in the presence of mRNA synthesis inhibitors and various cell death 
stimuli. When treated with the DNA damaging agent, doxorubicin (Dox), H1299p53tsPro 
cells were more sensitive to the DNA damage-than H1299p53tsArg cells, but not to 
cycloheximide (CHX)- or thapsigargin (TG)-induced cell death (Fig. 4A).
In mice, the PRD consists of two PXXP motifs highly resembling human p53. Mice 
expressing p53 lacking the four critical proline residues at loci 79, 82, 84, and 87 that make 
up the tandem PXXP sites (p53AXXA) were generated to study the role of the PRD in 
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Mdm2-mediated degradation of p5341,42. The p53AXXA mice develop normally and the 
transcriptional activation of target genes, apoptosis induction42, or acetylation43 is not 
impaired. MEFs from p53WT and p53AXXA mice showed comparable rate of proliferation in 
culture. We first subjected cultured MEF cells to UV light and determined that the mutation 
of the PXXP motif to AXXA of the PRD does not prevent stabilization of p53 protein by 
Western blotting (Fig 4B). Analysis of the dying cells revealed that when treated with Dox 
the MEFWT compared with MEFAXXA cells showed a higher percentage of Annexin V-and 
PI-positive cells at 8 h (Fig. 4C). MEFs from p53wt mice were more susceptible to Dox-, 
UV irradiation-, hypoxia-, or hyperoxia-induced cell death than p53AXXA MEFs, especially 
in the presence of the transcription inhibitor, DRB at 8 h (Fig. 4D) and at 18 h 
(Supplementary Fig. 6A, B) after treatment with cell death inducers. However, MEFs were 
equally sensitive to thapsigargin (TG)- (Fig. 4D) or cycloheximide (CHX)-induced cell 
death (Fig. 4D and Supplementary Fig. 6). These findings suggest that when transcription is 
blocked, enhanced degradation of bcl-2 mRNA by the p53Pro variant makes cells more 
susceptible to DNA damage-induced cell death compared to cells in which the PRD is 
modified resulting in a longer half-life and higher bcl-2 mRNA levels. This was also true in 
the absence of the transcriptional inhibitor where in p53AXXA MEFs cell death was 
significantly reduced compared to p53wt MEFs. Further, p53wt and p53AXXA MEFs were 
infected with adenoviral vectors expressing p53Arg and p53Pro and then treated with Dox. 
Western blotting following infection with Ad-p53Arg and Ad-p53Pro showed that similar 
levels were expressed (Fig 4E). However, cell death in MEFs was significantly increased 
when infected with Ad-p53Pro and, as expected, p53wt MEFs gained resistance to cell death 
when infected with Ad-p53Arg (Fig. 4F). These findings further confirm that the p53Pro 
variant enhances decay of the anti-apoptotic Bcl-2 and thereby sensitizes cells to Dox-
induced cell death.
PRD of murine p53 also affects the mucous regulatory network
To determine whether the two PXXP motifs or the two threonines affect mRNA stability, we 
compared bcl-2 mRNA stability in MAECs and MEFs from wild-type p53 (p53wt), 
p53AXXA, and p53ΔP mice. Bcl-2 mRNA levels were higher in mutant alleles versus wild-
type in MEFs (Fig. 5A) and MAECs (Fig. 5D) and mRNA half-life was increased from 1.5 
to ~5 h in MEFs (Fig. 5B and Supplementary Fig. 2I) and 2 to ~4 h in MAECs (Fig. 5E and 
Supplementary Fig. 2J) from p53wt and p53AXXA mice, respectively, following activation of 
p53 with 10 mJ UV radiation. Bcl-2 protein levels were also increased in MEFs (Fig. 5C) 
and MAECs (Fig. 5F) from p53AXXA compared to p53WT mice. These results confirm that 
the murine p53 PRD, similar to the human p53 PRD, is crucial in affecting bcl-2 mRNA 
decay. Furthermore, the studies in murine cells show that modifying not only the prolines 
but also the threonines within the p53 PRD to alanines equally increased bcl-2 mRNA 
levels.
Because mucus levels increase in those individuals harboring the p53Arg variant, we 
investigated whether changes in murine PRD also affect expression of the mucus regulatory 
network. Mice with a deletion of the PRD (p53ΔP) or expressing p53 lacking the four critical 
proline residues at loci 79, 82, 84, and 87 that make up the tandem PXXP sites (p53AXXA) 
were generated to study the role of the PRD in Mdm2-mediated degradation of p5341,42. 
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MAECs isolated from wild type, p53AXXA, and p53ΔP mice and differentiated on air-liquid-
interface (ALI) cultures showed increased levels in SPDEF, Muc5ac, Muc5b, and mRNAs 
compared to the p53wt MAECs (Fig. 5G). Because MEFs express comparable levels of 
SPDEF transcripts as MAECs (Supplementary Fig. 6C), we conducted a ChIP assay to 
determine whether similar to the human cells p53 may interact with the murine SPDEF 
promoter region. A 0.7 kB region of the murine SPDEF promoter was recovered at 
significantly higher levels from p53AXXA compared to p53WT MEFs (Fig. 5H). A 6 kB 
upstream region was used as a negative control and showed no interaction in p53AXXA and 
p53WT MEFs (Fig. 5H). These findings confirmed that the murine SPDEF promoter also 
interacts with p53 and that replacing the prolines with alanines significantly increased 
affinity to the promoter region.
Further, we infected MAECs from p53AXXA and p53ΔP mice with adenoviral expression 
vector for GFP (Ad-GFP) or p53Pro (Ad-p53Pro) to test whether the p53Pro is protective from 
increased mucus production. Cells were allowed to differentiate in ALI cultures and 
analyzed for SPDEF, Muc5ac, and Muc5b mRNAs levels. Levels of these mRNAs were 
reduced when these cells were infected with Ad-p53Pro versus Ad-GFP (Fig. 5I). These 
findings further define the role of p53Pro variant as being protective from increased mucous 
production.
Another mouse strain in which threonines 76 and 86 were mutated to alanines (p53TTAA) 
was generated to remove putative Pin1 binding sites42. Because modification of the PRD 
within p53 appeared to modify the regulation of SPDEF and Bcl-2 and the human 
epidemiological data indicated that the p53 variants was associated with CB, we investigated 
expression of Muc5ac and Muc5b in the lung tissues not only of p53wt, p53AXXA, and p53ΔP 
mice but also of p53TTAA mice. Consistent with findings in human studies, increased Muc5b 
(Fig. 6A) and Muc5ac (Fig. 6B) mRNA levels were more pronounced in mice with 
mutations in the PRD compared to wild-type mice.
To test whether this effect is observed in the C57Bl/6 background that is considered most 
resistant to developing mucous cell metaplasia, we backcrossed the p53TTAA, p53ΔP and 
p53AXXA mice that were generated on the 129J background into C57Bl/6 background over 
at least 10 generations. Results showed that in 129J and C57Bl/6 mice the mutations in the 
p53 PRD also increased the number of mucous cells per mm basal lamina (Fig. 6C), that this 
genotype drives mucous differentiation irrespective of the more resistant genetic pool 
present in C57Bl/6 mice. In addition, immunostaining with Muc5ac antibodies showed that 
tissue sections from p53AXXA, p53TTAA, and p53ΔP mice compared with p53wt exhibited 
significantly more positivity for Muc5ac (Fig. 6D). Further, Bcl-2 and Muc5ac-positive cells 
in p53AXXA compared to p53WT mice are higher at 12 d after LPS instillation (Fig. 6E). 
While the total cell number per mm basal lamina is similar in p53WT and p53AXXA 12 d 
after LPS challenge the hyperplastic changes remain in p53AXXA but not p53WT mice (Fig. 
6F). These findings suggest and show that the p53 PRD is central in regulating mucous 
metaplastic changes at baseline and during the resolution of hyperplastic changes.
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The present study defines the PRD of p53 as a crucial region that affects regulation of 
SPDEF and Bcl-2 to drive the mucous hypersecretory phenotype in humans and in rodents. 
Within the PRD of p53, substitution of Pro in the PVAP motif to Arg or Ala or modification 
of Thr to Ala was sufficient to increase both SPDEF promoter activity and bcl-2 mRNA 
half-life and drive the mucous regulatory network at baseline and to sustain the mucous cells 
following a hyperplastic response.
It is generally believed that under physiological conditions, apoptosis induction by p53 
mainly depends on the transcription of a distinct set of cell death regulatory genes. p53 is a 
major transcription factor that affects numerous promoter regions44. The DNA-binding 
region of p53 is the main region to affect transcription of genes known to directly execute 
apoptosis including the TNF-R family members, such as CD95/Fas/Apo-1, DR4, DR5/
TRAIL-R1, and the Bcl-2 family members, such as Bax, Puma, Noxa, and Bid45. However, 
the present studies show that the PRD of p53 also enhances cell death by reducing bcl-2 
mRNA half-life through interactions with the 5'UTR region and suppressing expression of 
this central inhibitor of apoptosis.
Despite the previous reports that interaction of p53 with the P2 promoter region suppresses 
P2 promoter activity in primary airway and lung cancer cell lines9,13, we first suspected that 
p53 does not suppress bcl-2 promoter activity when we noticed that within the context of the 
full-length P1-M-P2 promoter. First, the extent of this suppression was not sufficient to 
explain the drastic reduction in Bcl-2 protein when p53 is activated and the P2 promoter 
region was able to suppress the P1-M promoter activity independently of p53. These 
observations led us to hypothesize that p53 affects bcl-2 mRNA stability instead. We found 
that P2 sequences are part of the 5'UTR of bcl-2 transcripts, which is consistent with 
previous studies reporting that P2 initiates a small percentage of transcripts in cells such as 
B cells46. Because of their extremely labile nature, as evidenced by the smears observed in 
Northern blot analyses11,12,46, previous attempts to characterize all the bcl-2 mRNA 
transcripts by techniques such as the S1 nuclease assay may not have been sufficiently 
sensitive. Although we also found the previously identified T2, a transcriptional start site 
located within the GC-rich region at −131311, the other transcriptional start sites, T1, T3, 
and T4 have previously not been reported. All these transcripts contain a region of P2 that 
affects mRNA stability.
The p53 interaction with the 5'UTR of bcl-2 mRNA was demonstrated by the following 
studies: 1) All four bcl-2 transcripts were precipitated from cell extracts with p53 antibodies; 
2) p53 was detected in pull-down assays using in vitro synthesized bcl-2 mRNA; 3) p53Pro 
more drastically than p53Arg destabilized endogenous bcl-2 mRNA and luciferase mRNA 
that was expressed from the P1-M-P2 luciferase constructs; and 4) Deletion or mutations of 
a 16 nucleotide region of P2 prolonged the luciferase mRNA half-life, demonstrating that 
p53 reduces bcl-2 mRNA half-life by interacting with this 16 nucleotide region within the 
5'UTR. Previous studies have found that the AU-rich elements (AREs) in the 3’UTR of 
bcl-2 mRNA can bind AUF1 and TINO that cause a 2–fold destabilization of the 
mRNA47,48 or Bcl-2 protein itself that is required for ARE-dependent degradation of its own 
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mRNA47. Nucleolin, another protein that interacts with the AREs, stabilizes the bcl-2 
mRNA49.
The p53-mediated decay required only the 5'UTR but is independent of the 3’UTR of bcl-2 
mRNA. The p53Pro variant may be more efficient than the p53Arg variant in forming a 
macromolecular complex that helps recruit RNA enzymes to target bcl-2 mRNA. We 
searched both the genome and transcriptome for exact matches to the 16 nucleotides that 
were important for the interaction and enhanced decay of bcl-2 mRNA. Two other exact 
matches were found in the genome, and both reside approximately 37.5kb away from the 
FRG2 and FRG2B genes on chromosomes 4 and 10, respectively, but neither of these 
positions are transcribed regions. No exact matches, other than in the bcl-2 5’ UTR, were 
found in a search of all RefSeq and GenBank mRNAs. Mutation of 4 nucleotides on either 
end of the 16 nucleotides did not fully stabilize the bcl-2 mRNA although these changes 
abolished interaction of p53 from cell extracts. These findings suggest that secondary 
structures of the bcl-2 mRNA rather than a specific nucleotide sequence may be important 
for interaction with p53. The participation of factors that may bind to P2 sequences and form 
a scaffold for p53 interaction are yet to be identified. One previous study has reported that 
p53 binds to the 5' UTR of cdk4 to inhibit TGF-beta-regulated translational of cdk450.
The similar half-life of bcl-2 mRNA in HAECs and p53-deficient H1299 cells suggests that 
the function of p53 to enhance decay is tightly regulated. In addition, the need to activate 
p53 by UV irradiation in order to reduce bcl-2 mRNA half-life in HAECs implies that either 
only activated p53 can interact with bcl-2 mRNA or that other factors may facilitate this 
interaction. A wide range of cellular stresses, such as DNA damage, telomere erosion, 
aberrant oncogene activation, or hypoxia cause p53 accumulation and activation, indicating 
that protein abundance may dictate function10. The observation that bcl-2 mRNA half-life in 
A549 cells was reduced without inducing a cellular stress response supports that p53 is 
either constitutively activated in these cells in regard to destabilizing bcl-2 mRNA or that 
the factor(s) required for p53 interaction with bcl-2 mRNA are present. However, because 
p53 levels are low in A549 cells, we speculate that post-translational modifications such as 
phosphorylation of various serine and threonine residues, acetylation, and methylation of 
specific p53 domains51 and/or cooperation with other transcription factors52 may be 
responsible for the interaction to enhance the decay of bcl-2 mRNA.
Modifying p53 expression in both SAOS-2 and HCT116 cells or simply substituting the 
proline or threonine residues within the PRD of p53 affected bcl-2 mRNA levels and mRNA 
half-life in human and murine cells. The fact that it is not only the substitution of the 
conserved PXXP motif but also the substitution of threonines with alanines affecting the 
decay of bcl-2 mRNA across cell types and species suggests that it is the conformational 
change that is introduced by any modification within the PRD to be the primary cause for 
the ability of p53 to interact with higher affinity to SPDEF promoter or bcl-2 mRNA. The 
PRD lies within the N-terminal region of p53 (aa 61–94) and is characterized by two 
transactivation domains (TAD) that are required for transcriptional activation of target 
genes51. Previous studies have focused on the contribution of the PRD to the regulation of 
p53 stability, transactivation ability, and induction of transcription-independent 
apoptosis32,33,53. p53Pro activates expression of certain genes by binding more strongly to 
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TAFII70 and TAFII32, major components of the basic transcriptional machinery, than does 
p53Arg33. That p53Arg compared to p53Pro interacts stronger with both the P2 sequences of 
the bcl-2 mRNA and the SPDEF promoter is consistent with those observations. Consistent 
with our findings, a previous study had reported that Bcl-2 immunopositivity tended to be 
more in tumors with the p53Arg variant54. However, the present studies are the first to link 
the PRD of p53 to regulating mRNA stability.
At baseline, p53AXXA mice show increased metaplastic mucous cells compared to p53WT 
mice while the total airway epithelial cell numbers are similar, likely due to increased 
SPDEF levels. However, after LPS instillation that caused a hyperplastic response equally in 
p53+/+ and p53−/− mice, the resolution of hyperplasia was intact in p53+/+ mice but was 
disrupted in p53−/− and p53AXXA mice. The induction of mucous expression in mice 
instilled with LPS is independent of SPDEF, as during such inflammatory responses IL-1β55 
and neutrophil elastase56 cause increased expression of Muc5ac and Bcl-257. However, 
sustained hyperplasia in p53−/− and p53AXXA mice is likely due to increased Bcl-2 
expression in these mice.
When transcription is blocked with 5,6-dichloro-1-beta-D-ribobenzimidazole (DRB), p53Pro 
more efficiently causes cell death than p53Arg due to drastically reduced Bcl-2 levels caused 
by the high bcl-2 mRNA decay rate by p53Pro. The finding that cyclohexamide- or 
thapsigargin-induced cell death equally well in both H1299p53tsArg and H1299p53tsPro 
cells when co-treated with DRB may suggest that Bcl-2 does not affect protein shutdown- or 
ER-induced cell death but DNA damage-induced cell death caused by doxorubicin, UV 
irradiation, hyperoxia, or hypoxia. Cell type differences in apoptotic pathways induced by 
p53Arg and p53Pro may explain the findings that the p53Pro was found to be less apoptotic58. 
Findings from our studies suggest that using a combination of DNA polymerase II inhibitors 
to enhance bcl-2 mRNA decay along with radiation and chemotherapy may better target 
cancers of individuals harboring the p53Arg genotype rather than using DNA damaging 
agents only. While the association of the p53 polymorphisms with cancer incidence is 
inconclusive, several studies have suggested that individuals homozygote for p53Arg have a 
better response and survival rate following chemo- and radiation therapy for head and neck, 
breast, and lung cancers (reviewed in59).
The effect of this SNP on the mucous differentiation pathway is highly conserved, 
suggesting that these mice with modifications in the PRD of p53 closely reflect the 
susceptibility in humans and should be most appropriate for screening potential drugs to 
treat chronic mucous hypersecretion. Many drugs that are screened in mice fail in human 
trials because of vast differences in pathways. Testing potential drugs in mice that replicate 
the disease in humans, such as the p53AXXA mice, not only would help in improve design 
but also increase the likelihood of success in human clinical trials. Similar strategies that use 
genetically engineered mouse models have shown success in predicting the outcome of 
clinical trials60,61.
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The LSC (Lovelace Smokers’ Cohort) is a well-characterized cohort of current and former 
smokers in New Mexico. Recruitment, inclusion, and exclusion criteria have been described 
previously62,63. Briefly, study subjects were drawn from a cohort study Albuquerque, NM 
and its surrounding communities. Most participants were recruited through newspaper or 
television advertisements and were paid a small stipend for their participation. Subjects were 
included in the study if they were ages 40 to 75 years, former or current smokers with a 
minimum smoking history of 20 pack-years on initial screening, and able to understand 
English. Information related to demographics, respiratory diseases, and smoking was 
obtained by self-report from all study participants via a questionnaire. Spirometry was 
obtained on all subjects by certified and registered respiratory therapists strictly adhering to 
the 1994 American Thoracic Society (ATS) guidelines. The LSC disproportionately enrolled 
women ever-smokers since the disease prevalence from 1998 onwards is significantly higher 
among women than men64 and since women are underrepresented in most COPD studies in 
the United States65. This study is approved by the Western Institutional Review Board 
(Olympia, WA; #20031684) and all subjects sign informed consent for their participation.
Animals
Pathogen-free wild-type 129J and C57BL/6J mice and p53−/+ breeders were purchased from 
The Jackson Laboratory (Ben Harbor, ME). p53wt, p53AXXA, p53TTAA, and p53ΔP mice on 
129J background were provided by Dr. Geoffrey M. Wahl (Salk Institute for Biological 
Studies, LaJolla, California). Mice were housed in isolated cages under specific pathogen-
free conditions and bred at LRRI for the described studies. The p53ΔP mice were genotyped 
by standard PCR that show different products from wild-type mice and the AXXA and 
TTAA mice were genotyped using restriction digestion of PCR amplified products to 
distinguish the knock-in from wild-type mice (primer sequences can be found in 
Supplementary Table 3). These mice were also backcrossed for at least 10 generation into 
the C57BL6 background. Right cranial lung lobes were removed from mice and tissue 
homogenized using TissueLyser II (Retsch, Newtown, PA) and RNA isolated and qRT-PCR 
performed as described previously29. Mice were randomized by weight for each study. 
p53+/+ and p53−/− mice were intransally instilled with 60 µg LPS as described29. Left lungs 
were inflated and fixed at 25 mm pressure with zinc formalin for preparing tissue sections 
which were stained with Alcian blue (AB), hematoxylin (H) and eosin (E) or were 
immunostained. Images were captured using NanoZoomer Digital Pathology slide scanner 
(Hamamatsu, Bridgewater, NJ) and epithelial and mucus cells quantified using Visiopharm 
Integration System (VIS) software (Horsholm, Denmark). For all mice, epithelial cells in the 
axial airway of the left lung at generation 4 or 5 are quantified. A minimum of 3 adult mice 
were used for isolation of MAECs that were cultured for differentiation on Transwell inserts 
according to described methods66. All experiments were approved by the Institutional 
Animal Care and Use Committee of Lovelace Respiratory Research Institute (LRRI) and 
were conducted at LRRI, a facility approved by the Association for the Assessment and 
Accreditation for Laboratory Animal Care International.
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Primary human airway epithelial cells (HAECs) from individuals homozygous for the 
p53Arg and p53Pro variants were obtained from lungs under the protocol and consent form 
approved by the University of North Carolina School of Medicine Committee on the 
Protection of the Rights of Human Subjects. HAECs from each individual and those 
purchased from Clontech (Walkersville, HD), and AALEB cells (Immortalized and 
transformed human airway epithelial cells)67 were maintained in BGEM media (Cambrex 
Biosciences, Walkersville, HD) with various supplements as described68. After seeding 
primary HAECs on Transwell membranes and differentiating them on air-liquid interface, 
membrane quarters were used for qRT-PCR and membrane halves embedded in paraffin. 
Sections were stained with AB/H&E and imaged with Nikon (Irvine, CA) E600 light 
microscope and 40X images captured with Nikon DXM1200F camera using ACT-1 
software. Epithelial and mucus cells quantified using Visiopharm Integration System (VIS) 
software.
SAOS-2 (human osteosarcoma cell line, ATCC HTB-85), Calu-3 (human lung 
Adenocarcinoma cell line, ATCC HTB-55), H23 (NCI-H23, lung Adenocarcinoma, ATCC 
CRL-5800), HBEC-2 (human immortalized airway epithelial cells), and A549 
(Immortalized and transformed human alveolar cells, ATCC CCL-185) cells were 
maintained in Dulbecco’s modified Eagle’s media (DMEM) supplemented with 10% FBS. 
Expression vectors for p53Arg or p53Pro variants at codon 72 have been shown to induce cell 
death differentially in SAOS-2 cells58. The H1299 cell line (NCI-H1299, ATCC 
CRL-5803), a p53-deficient cell line that is derived from a non-small cell lung cancer, was 
used to generate stable cell lines by transfecting with pCMV-neo-bam tsp53Arg72 or pCMV-
neo-bam tsp53Pro72 plasmids (gift from Dr. Murphy, University of Pennsylvania, PA) that 
express temperature-sensitive p53 variants. These variants are essentially inactive at 37°C 
but are activated when cells are shifted to 32°C. Clones expressing similar p53 protein levels 
were selected for further experiments (see Supplementary Fig. 5). H1299 cells and those 
harboring temperature-sensitive p53 variants for Arg and Pro at codon 72 were maintained 
in RPMI-40 (Gibco) with 10% FBS, and 2 mM glutamine, and 400 µg/ml G418 (Sigma 
Chemicals).
Mouse embryonic fibroblasts (MEFs) from p53wt, p53ΔP, p53TTAA, and p53AXXA mice 
were derived from day 14.5–16 embryos, and were cultured in DMEM supplemented with 
10% FBS and were used for experiments at passages 3–8. MEFs were infected (10 MOI) 
with adenoviruses expressing p53Arg or p53Pro. Twenty-four hours later, cells were washed 
and treated with 1 µM doxorubicin for 24 h. Cells were counted and harvested for western 
blot analyses. SAOS-2 cells stably transfected with either p53-expressing plasmid 
(SAOSp53) or vector only (SAOS-2Ctr) were a gift from Dr. Michael Resnick (National 
Institute of Health Environmental Sciences; Dallas, TX), and were maintained in DMEM 
supplemented with 10% FBS and 0.5 mg/ml G418.
Cell Death Assay
Following treatment with 50 ng/ml DRB and either 1µM doxorubicin, 10 µM 
cyclohexamide, or 1 µM thapsigargin, viable cell numbers were quantified using trypan blue 
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exclusion method. Cells were also irradiated with 10 mJ UV light, were treated with hypoxia 
(5% O2/95% nitrogen) or hyperoxia (95% O2/5% nitrogen) for 30 m at room temperature 
and were cultured in 37°C incubator with 5% CO2/ 95% air. Cells were harvested 24 h after 
treatment by trypsinization and cell numbers were quantified using trypan blue exclusion 
method. For AnnexinV-PI staining, approximately ~ 105 cells were also stained in 1X 
binding buffer (0.01 M HEPES, pH 7.4; 0.14 M NaCl; 0.25 mM CaCl2) using 5 l propidium 
iodide (Sigma) and 10 µl of Annexin V-FITC (BD PharMingen). The reaction was incubated 
in the dark for 15 min at room temperature and the percentage of FITC- and PI-positive cells 
were collected on FACS Canto (BD Biosciences; San Jose, CA) flow cytometer and 
analyzed using FlowJo software (ver 7.6.3; TreeStar, San Carlos, CA).
Generation of Deletion Constructs and Site-Directed Mutagenesis
The generation of the P1-M-P2 luciferase construct has been described previously13 and the 
P1-M-P2 constructs in which P2 was serially deleted (P1-M-P2Δ1–10) were generated by 
amplifying the P2 region with primers listed in Supplementary Table 1 that introduced the 
upstream Bgl-II and a downstream Hind-III site. The amplified products were then used to 
replace the full-length P2 sequence that was removed by restriction digestion using Bgl-II 
and Hind III. For in vitro mRNA synthesis, the P1-P2Δ10 luciferase construct was cloned in 
to PCRIITOPO vector (Invitrogen) that has the dual promoter system for REMSA.
The 50-nucleotide-long forward and their reverse oligonucleotides sets were designed 
having the Xba-I in the upstream sequence and Hind-III restriction site on the downstream 
sequence. The 16-nucleotide sequences with putative p53-interaction sites were mutated by 
changing the purines to pyrimidines as shown by the underlined sequences in 
Supplementary Table 2. The oligonucleotides were annealed, double-stranded DNA 
generated, and following digestion with Xba-I and Hind-III restriction fragments were 
cloned into a pCR-II dual promoter vector. These plasmids were then used for in vitro 
transcription (IVT) and pull-down using 1:500 diluted p53 antibody (sc-98, Santa Cruz 
Biotechnology, CA).
Two deletion mutants were generated in the dual promoter vector, pCR-2.1, harboring the 
P2 region using Quickchange site-directed mutagenesis kit (Stratagene) according to 
manufacturer’s protocol. The resulting mutant constructs, pCR-2.1 P2(−482/−468) and 
PCR-2.1 P2(−443/−429), in which 16 and 14 nucleotides, respectively, had been deleted 
were used for IVT synthesis and pull-downs using the p53 antibody (sc-98, Santa Cruz). The 
P1MP2Δ(−443/−429) luciferase construct in which 16 nucleotides were deleted from 
P1MP2 luciferase plasmid and PIMP2Δ(−443/−439 and −433/−429) were generated at 
Mutagenex Inc. (Somerset, NJ). These deleted plasmids were used for transient transfection 
in HCT116 p53 positive cells to determine the effect of this deletion on luciferase mRNA 
half-life. Both SPDEF promoter deletion mutants (Mut11 and Mut21) were also generated at 
Mutagenex.
RNA Extraction and RT-PCR
Total RNA was extracted from Calu-3, A549, AALEB, SAOS-2, H1299, HBEC-2, NHBEC, 
and transfected H1299 cells using TRI reagent (TR-118; Molecular Research Centre, Inc.) 
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as described by the manufacturer. For cDNA synthesis, 1µg of total RNA or RNA treated 
with RNAse free DNase (Invitrogen) were reverse-transcribed with Random Hexamers 
(Promega). Primers with the following sequences: M Forward: 5’-
GCAGGACCAFFAGGAGGAGA-3’, M Reverse 5’ GGTGG GGGAGG TTTTATTT-3’, 
and P2 Forward: 5’- CGATC TGGAA ATCCT CCTAATT -3’ and P2 Reverse: 
5’TTGGCATGAGATGCAGGAAA-3 were designed to amplify the M and P2 regions of 
the bcl-2 promoter. After denaturing at 95°C for 5 min, reactions were amplified for 35 
cycles using annealing temperatures of 55°C for M primers and 60°C for P2 primers.
5’Rapid Amplification of cDNA Ends (RACE)
To identify the 5'UTR, we used the rapid amplification of cDNA ends (RACE) kit 
(Invitrogen; San Diego, CA) on RNA isolated from HAECs according to the manufacturer’s 
instructions. Briefly, total RNA (5 µg) was dephosphorylated with 10 U/µl calf intestinal 
phosphatase (CIP) and treated with 0.5U/µl tobacco acid phosphatase (TAP) to removes the 
5’ CAP structure. The 5’gene racer oligo was ligated to the RNA using T4 RNA ligase and 
the first strand cDNA was synthesized using random hexamers and superscript III RT. 
Transcripts were identified by PCR using the gene racer primer R1 and primers specific to 
the M region (M1: 5’GTGGGGGAGGTTTTATTT-3’) or bcl-2 open reading frame (ORF1: 
5’CGCTGGGAGAACAGGGTACGATAA -3’). Amplification using nested racer primer 
R2 and gene-specific primers specific to the M region (M2: 5’-
ATGACTGCTACGAAGTTCTCCC-3’) and the bcl-2 open-reading frame (ORF2: 5’-
TGGCGCACGCTGGGAGAACA-3) were used to ensure specificity of products, followed 
by cloning into TOP10 vector (Invitrogen, CA) for sequencing.
mRNA Half-Life Studies
Following treatment with the transcription inhibitor 5,6-dichloro-1-beta-D-
ribobenzimidazole (DRB) (Sigma-Aldrich) total RNA was extracted using TRIzol reagent. 
RNA levels were normalized using 18S rRNA and GAPDH amplified from the same RNA 
samples using Pre-Developed 18S rRNA (VIC-MGM) and hGAPDH (ABI Assay-on-
Demand FAM-MGM probe). Relative mRNA abundance was calculated using the ΔΔCt 
method and mRNA half-life was calculated as described43. The primers and probe for 
detecting luciferase mRNA expression by qRT-PCR were LUCForward-
ACCTCCGTACTATCCTTTGGAAGAA LUCReverse-
GGAACTGCGGCATATCGTGATA and the probe sequence with the dye LUC-FAM-
ACTGCGGGAGAACAA.
Western Blot Analysis
Cell extracts were prepared using RIPA buffer (20mM Tris, pH 7.4, 137 mM NaCl, 1% 
NP-40, 0.25% Deoxycholate, 0.1% SDS, 1mM EDTA and 1% protease inhibitor cocktail). 
Protein concentration was determined by BCA kit (Pierce; Rockford, IL) and 100 µg protein 
was analyzed by Western blotting as described previously69. Anti-p53 (sc-98, Santa Cruz) 
was used at 1:1000 (2 µg/mL) dilution and anti-Bcl-2 (sc-492, Santa Cruz) and anti-β-actin 
(Sigma) were used at 1:1000 dilutions. SPDEF antibodies (gift from Dr. Jeffery Whitsett, 
Children’s Hospital, University of Cincinnati, OH) were used at 1:5000 dilution. Proteins 
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were detected using ECL and visualized by chemiluminescence (Perkin Elmer, Waltham, 
MA) using the FujiFilm Image Reader LAS-4000 (Valhalla, NY). The uncropped scans of 
the most important Western blots are included as a supplementary figure in the 
Supplementary Information.
Co-Immunoprecipitation Assays
Immunoprecipitation of protein-RNA complexes was performed as described previously70. 
H1299p53ts cells were incubated at 32°C, harvested (8×107), and proteins cross-linked using 
formaldehyde (Sigma) at a final concentration of 0.5% (v/v) and incubated at room 
temperature for 10 min. Cross-linking was quenched with glycine (pH 7.0, 0.25M final 
concentration) and cells were lysed with three rounds of sonication in 1ml of RIPA buffer 
containing protease inhibitors. An aliquot of the cell lysate (500µl each) was mixed with 
20µl of protein-A Sepharose beads for 1 h at 4°C followed by centrifugation at 400g for 5 
min. The pre-cleared supernatant was diluted with RIPA buffer (250µl) containing RNAsin 
and protease inhibitors, mixed with polyclonal anti-p53 (0.2 µg/µl) (sc-98, Santa-Cruz) or 
IgG (0.2µg/ml) and incubated overnight at 4°C with slow mixing. Protein-A Sepharose 
beads (100µl) were added to the samples followed by incubation at 4°C for 3 h. The 
Sepharose beads were washed five times with RIPA buffer, beads were centrifuged for 5 
min at 200g and mRNA-protein complexes eluted with 120µl hot SDS and boiled for 5 min. 
Beads were incubated at 70°C for 45 min to reverse cross-linking and then centrifuged for 5 
min at 13,000g and eluted. From both p53 and IgG1, 20 µl samples were removed for 
Western blot analysis. RNA was extracted from the remaining samples using TRIzol 
(Invitrogen) according to manufacturer’s protocol, treated with DNAse I, and used as a 
template for qRT-PCR using probe and primer set for human Bcl-2 (ABI Assay-on-Demand 
FAM-MGM probe) and to synthesize cDNA using random hexamer primers (OmniScript 
Invitrogen). PCR was performed using 5 µl of the cDNA samples using primer sets for the 
four transcripts: T1 Forward: 5’CCTGC CGCGG CGCCT TTAAC3’ Reverse: 5’-ATGAC 
TGCTA CGAAG TTCTCCC-3’, T2 Forward: 5’GCAGG ACCAG GAGGA GGAGA3’ 
Reverse: 5’GGTGG GGAGG TTTTATTT-3’ .T3 Forward: 5’- CGATC TGGAA ATCCT 
CCTAATT -3’ Reverse: 5’-TTGGC ATGAG ATGCA GGAAA-3’and T4 Forward: 5’-
TGGGG TGGGA GCTGG GGCGA-3’ Reverse: 5’-CCCCC GTTGC TTTTCCT-3’ regions 
of the Bcl-2 5'UTR region.
Chromatin-Immunoprecipitation (ChIP) Assay
H1299 cells harboring temperature-sensitive p53Arg or p53Pro variants, and MEFs from 
p53WT and p53AXXA cells were used for ChIP assays as described previously43. Briefly, 
cells were fixed with 1% formaldehyde, and the reaction was quenched using 1.25 M 
glycine and scraped into cold PBS containing protease inhibitors. ChIP was performed using 
the Magna ChIP G kit (MAGNA0002; EMD Millipore) as described by the manufacturer. 
Sonicated nuclear fractions were incubated with p53 antibody using mouse monoclonal 
(sc-98, clone Pab1801; Santa Cruz Biotechnology, Inc.) and rabbit polyclonal (sc-6324, 
clone FL393; Santa Cruz Biotechnology, Inc.) for human and murine p53, respectively. 
DNA identification was confirmed with PCR using the following primers specific for the 
human and murine SPDEF promoter regions: CTGATCCATCTTAGAACCCCAGCCC 
(forward), and GGATCCATGCCCTGACAGCTAGG (reverse); and 
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GGAGAGAGAACTCAGCAGTTAAG (forward) and GTGTCACCACACCTGACTATC 
(reverse), respectively. The 4 and 6 kb upstream for human and murine SPDEF regions, 
respectively used the following specific primers: CTGTGAGTGAGACAGGCAATGACCC 
(forward) and TTGGGACCAGAGAGGCTAGGGAC (reverse); and 
GTTTGACTCTCTCCTGGCTTTC (forward) and CATCTACTAC ACGCCAAGTT CC 
(reverse), respectively.
In-Vitro RNA Transcription (IVT) and RNA Pull-Downs
Biotinylated RNA transcripts were synthesized using the in vitro transcription kit from Enzo 
Life sciences (Farmingdale, NY) as described by the manufacturer. Briefly, reactions were 
performed using T7 (sense) and SP6 (antisense) promoters to synthesize P2 RNA from 
pCR-2.1 P2. In vitro transcription (IVT) reactions contained 1 µg of linearized plasmid 
template treated with Proteinase K (100 µg/ml) and 0.5% SDS and reaction incubated for 30 
min at 50°C. After phenol/chloroform extraction, DNA was precipitated overnight by adding 
ethanol. DNA was resuspended in RNAase/DNAase-free water (Hyclone, Thermo 
Scientific, Logan, UT) and incubated with transcription reaction for 1 hr at 37°C, before 
treatment with RNAse-free DNAse-1 (Turbo, Enzo Life Science, Farmingdale, NY). Biotin-
labeled probes were purified by precipitating with 4 M LiCl and 100% ethanol. The RNA 
pellet was dissolved in 2X TEN (20 mM Tris-HCL pH 8.0, 2 mM EDTA pH 8.0 and 
500mM NaCl) and quantified. Cytosolic S-100 extract was prepared using H1299p53ts cells 
incubated at 32°C. Cells were washed twice in cold PBS and then suspended in 500 µl of 
buffer D (10mM Hepes (pH 8.0), 3mM MgCl2, 40mM KCl, 0.1% protease inhibitor cocktail 
(Sigma), 0.2% NP-40 (Nonidet P40), 10% glycerol, and 1 mM DTT (dithiothreitol) and 
incubated on ice for 10 min. The cells were lysed with 50 bursts using a Branson sonifier 25 
sonicator (Thomas Scientific). The lysate was centrifuged at 10,000g for 2 min in order to 
pellet nuclei, followed by centrifugation at 20,000g for 1h at 4°C to produce the cytosolic 
S-100 extract. IVT RNA was incubated with 300 µg of S-100 extract in 2X TENT buffer 
(20mM Tris-HCL pH 8.0, 2mM EDTA pH 8.0, 500mM NaCl and 0.5% v/v Triton X-100) 
for 30min at room temperature with gentle mixing. Pull-downs were performed in the 
presence of 1% Triton X-100 using Dynabeads M-280 cross-linked to steptavidin beads 
(Invitrogen). Each pull down reaction was incubated with 300 µg of S-100 extract and 
Dynabeads for 30 min at room temperature with gentle mixing. Dynabeads were settled with 
magnetic beads and centrifuged for 5 min at 1,000g. The RNA-protein-bead complexes were 
washed three times, eluted with 30 µl hot SDS and pull-down products analyzed for p53 by 
Western blotting. The chromosome immunoprecipitation assay (ChIP) was performed as we 
have described43.
Gene Silencing in Differentiated HAECs
Differentiated HACEs were transduced with retroviral expression vectors for Bcl-2 shRNA, 
SPDEF shRNA and control shRNA (Origene Technologies, Inc., Rockville MD) as per 
manufacturer’s instructions. Transwell membranes were harvested and expression of certain 
genes analyzed by qRT-PCR and Western blot analyses.
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Grouped results from at least three or four different sets of experiments were expressed as 
mean with SEM, and differences between groups were assessed for significance by 
Student’s t test when data were available in only two groups. When data were available in 
more than two groups, analysis of variance (ANOVA) was used to perform pair-wise 
comparison. When significant main effects were detected (P < 0.05), Fisher least significant 
difference test was used to determine the differences between groups. A P value of 0.05 was 
considered to indicate statistical significance. The difference in the mean CT values from 
qRT-PCR amplifications between the two homozygote genotypes of HAECs was assessed 
with a two-sample t-test. Both, the difference and the difference plus one standard error 
were summarized by expressing as fold change.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MCM is sustained longer in p53−/− compared to p53+/+ mice
(A) p53+/+ and p53−/− were instilled with LPS and MCM was quantified after 5, 8, and 12d 
of instillation. MC/mm basal lamina is reduced in p53+/+ but is sustained in p53−/− mice at 
12 d following LPS instillation. (B) Lung tissue sections from p53+/+ and p53−/− mice at 
12d post instillation were immunostained with antibodies to Bcl-2 and Muc5ac and with 
DAPI to visualize nuclei (scale bar 10 µm). (C) Percentages for Bcl-2- and Muc5ac-positive 
cells. (D) Cell numbers of Bcl-2- and Muc5ac-positive cells per millimeter basal lamina. 
Bars = group means ± standard error from the mean (n = 3–5 mice/group); * P<0.05.
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Figure 2. p53 reduces Bcl-2 protein and mRNA levels by destabilizing bcl-2 mRNA
(A) Bcl-2 mRNA levels in p53+/+ and p53−/− HCT116 quantified by qRT-PCR. (B) Bcl-2 
mRNA half-life in p53+/+ and p53−/− HCT116 cells determined after DRB treatment for 0, 
2, 4, 6, and 8h and Bcl-2 mRNA quantified by qRT-PCR. (C) Bcl-2 protein levels in p53+/+ 
and p53−/− HCT116 cells with densitometric quantification normalized to actin content 
shown in the lower panel. (D) Bcl-2 mRNA levels and mRNA half-life (E) in p53−/− and 
p53+/+ primary mouse airway epithelial cells (MAECs). (F) RT-PCR for T1, T2, T3 and T4 
bcl-2 transcripts of HAECs. (G) Luciferase mRNA half-life analyzed in H1299p53ts cells 
Chand et al. Page 25













transfected with P1MP2-Δ3, Δ4, Δ5, and Δ6 -luciferase constructs, treated with DRB at 16 h 
post-transfection and RNA collected at 0, 2, 4, and 6h. (H) Luciferase activity for P1MP2-
Δ4 and Δ5 constructs measured using firefly (FL) to renilla (RL) luciferase ratio. (I) The P2 
region cloned in the pCRII dual promoter vector was used to generate Bio-11-UTP-labeled 
sense and anti-sense RNA using the T7 and Sp6 promoters, respectively; the labeled RNAs 
were pull-down using H1299p53ts S-100 cytosolic extracts. p53 was detected in pull-down 
products using sense (lane 3) but not anti-sense RNA (lane 4). Bio-11-UTP-labeled sense 
RNA prepared from two deletions introduced into the P2-containing constructs - pCR-II 
P2(−482/−468) and pCR-II P2(−443/−429). Pull-down assays performed with sense RNA 
from pCR-II P2(−482/−468) (lane 1), pCR-II P2(−443/−429) (lane 2). Densitometric 
quantification of pull-down products normalized to the input shown in left panel. (J) 
Luciferase mRNA half-life for P1MP2Δ(−443/−429,−443/−439,−433/−429) luciferase and 
wild-type P1MP2 luciferase vectors following transfection into HCT116 p53+/+ cells (K) 
The luciferase activity for wild-type P1MP2 luciferase and P1MP2Δ−443/−439,−433/−429) 
luciferase constructs. (L) Cell extracts prepared from H1299 and H1299p53ts cells 
maintained at 32°C were immunoprecipitated using anti-p53 or IgG1 and probed for p53 on 
a Western blot. Analysis of pull-down products for bcl-2 mRNA by qRT-PCR was 
normalized to the total protein and input. Bars = group means ± standard error from the 
mean (n = 3 different treatments/group); * P<0.05.
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Figure 3. p53Arg interacts and upregulates SPDEF to stimulate the mucous regulatory network
(A) Bcl-2 mRNA levels in primary HAECArg and HAECPro cultures. (B) Bcl-2 mRNA half-
life in primary HAECs 2 h after activating p53 by exposing cells to 10 mJ UV. HAECs from 
three individuals with p53Arg or the p53Pro variants were treated with DRB and Bcl-2 
mRNA half-life was determined at 0, 2, 4, 6, and 8h. (C) Bcl-2 protein levels in HAECArg 
and HAECPro cells with densitometric quantification normalized to actin content shown in 
the lower panel. (D) Comparison of MUC5AC mRNA levels by qRT-PCR in HAECArg and 
HAECPro cultures from 10 individuals each. HAECs were differentiated on ALI cultures. 
(E) MUC5AC protein in washes from HAECArg and HAECPro cultures from 10 individuals 
each determined by ELISA. (F) The number of mucous cells per mm basal lamina 
determined by counting cells using morphometry. (G) Validation of expression of 
MUC5AC, MUC5B, and SPDEF mRNAs by qRT-PCR based on microarray results from 
HAECArg and HAECPro cultures from 10 individuals each. (H) Expression of p53Pro in 
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HAECArg cells using adenoviral expression vector reduces expression of MUC5AC, 
MUC5B, and SPDEF. (I) Expression of p53Arg in HAECPro cells using adenoviral 
expression vector increases expression of MUC5AC, MUC5B, and SPDEF. (J) SPDEF 
promoter in pGL3Basic exhibits a higher promoter activity in the H1299tsArg cells 
compared to H1299tsPro cells. (K) ChIP assay using p53 antibodies from H1299tsArg and 
H1299tsPro cells showed that significantly more DNA was pulled down from the Arg cells 
compared to the Pro cells. Input denotes that similar DNA amounts were used for the pull-
down experiment. Interaction of p53 is visible when using primers specific to the −0.3 kB 
region but absent when using primers specific to the −4kB region. (L) H1299, H1299tsArg 
and H1299tsPro cells transfected with promoter constructs for SPDEF, deletion mutant 11 
and deletion mutant 12 in pGL3Basic and promoter activities were measured. Promoter 
activity was reduced for both cell types with both mutants. Bars = group means ± standard 
error from the mean (n = 3 different treatments/group). *P<0.05.
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Figure 4. The proline-rich domain of p53 affects DNA damage-induced cell death in airway 
epithelial cells
(A) H1299p53tsArg and H1299p53tsPro cells treated with 50 ng/ml DRB, and either 1 µM 
doxorubicin, 10 µM cyclohexamide, or 1 µM thapsigargin, and cell numbers quantified 48 h 
later. (B) p53 levels were increased in p53WT and p53AXXA MEFs when treated with 10 mJ 
UV irradiation. (C) p53WT and p53AXXA MEFs treated with 10 mJ UV irradiation in the 
presence of 50 ng/ml DRB and cell death analyzed by Annexin V and propidium iodide (PI) 
staining. (D) Quantification of Annexin V-positive cells in p53WT and p53AXXA MEFs 
following treatment for 8 h with 50 ng/ml DRB and either 10 mJ UV irradiation, 1 µM 
doxorubicin, 5% O2 (hypoxia), 95% O2 (hyperoxia), or 1 µM thapsigargin. (E) Western blot 
verifying the presence of p53 after infection of p53WT and p53AXXA MEFs with adenoviral 
vectors expressing p53Arg or p53Pro. (F) p53WT and p53AXXA MEFs were either left 
untreated (control) or infected with adenoviral vectors for p53Arg or p53Pro then treated with 
1µM doxorubicin for 24 h and cell numbers quantified. Bars = group means ± standard error 
from the mean (n = 3 different treatments/group) ; * P<0.05; ** P<0.01.
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Figure 5. The proline-rich domain of murine p53 regulates bcl-2 mRNA levels and half-life, and 
the expression of mucous differentiation genes
Bcl-2 mRNA levels (A, D) and mRNA half-life (B, E) in MEFs (A, B) and in MAECs (D, 
E), respectively from p53WT, p53ΔP, and p53AXXA mice after treatment with 10 mJ UV 
light was determined after treating with DRB and collecting RNA samples at 0, 2, 4, 6, 8, 10 
and 12h for analysis by qRT-PCR. Experiments were repeated at least 3 times with each 
experiment containing 3–4 independent repeats. Bcl-2 protein levels in MEFs (C) and 
MAECs (F) from p53WT and p53AXXA mice with densitometric quantification of Bcl-2 
protein levels normalized to actin content shown in the lower panels. (G) MAECs isolated 
from p53WT, p53AXXA and p53ΔP/ΔP mice were differentiated on air-liquid interface cultures 
on Transwell membranes and RNA analyzed by qRT-PCR for Muc5ac, Muc5b, and SPDEF. 
(H) ChIP assay using p53 antibodies from p53WT and p53AXXA MEFs showed that 
significantly more DNA was pulled down from the AXXA cells compared to the WT cells. 
Input denotes that similar DNA amounts were used for the pull-down experiment. 
Interaction of p53 is visible when using primers specific to the −0.7 kB region but absent 
when using primers specific to the −6 kB region. (I) p53AXXA and p53ΔP MAECs were 
differentiated on air-liquid interface cultures and infected with adenoviruses AdGFP 
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(control) and AdPro. Isolated RNA was analyzed by qRT-PCR for Muc5ac, Muc5b, and 
SPDEF. Bars = group means ± standard error from the mean (n = 3 different treatments/
group); * P<0.05.
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Figure 6. The proline-rich domain of p53 is crucial in regulating mucous differentiation
RNA from the right cranial lung lobes of p53WT, p53AXXA and p53ΔP mice were analyzed 
by qRT-PCR for Muc5b (A) and Muc5ac (B). (C) Mucous cells per mm basal lamina were 
quantified in the axial airways of p53WT, p53AXXA, p53ΔP, and p53TTAA mice on 129J and 
C57Bl/6 backgrounds. Bars = group means ± standard error from the mean (n = 6 mice/
group). * denotes statistically significant difference. (D) Representative micrographs of 
airway tissue sections from p53WT, p53AXXA, p53ΔP, and p53TTAA mice on 129J 
immunostained for Muc5ac (red) and counterstained with DAPI (blue) for nuclear staining. 
Scale - 10 µm. (E) p53WT and p53AXXA mice were instilled with LPS and changes in Bcl-2- 
and Muc5ac-positive cells was quantified after 12d of instillation. Representative 
micrographs from p53WT and p53AXXA mice airway sections at 12 d post LPS instillation 
showing the Bcl-2 (green) and Muc5ac (red) immunostained cells and with DAPI (blue) 
nuclear counterstaining. Scale - 5 µm. (F) Total airway epithelial cell numbers per 
millimeter basal lamina at 0 d (baseline) and at 12 d post LPS instillation. Bars = group 
means ± standard error from the mean (n = > 3 mice/group); * P<0.05.
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